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AbstrAct
Introduction Cognitive processing therapy (CPT) is widely 
regarded as a safe and effective first-line treatment for 
individuals with post-traumatic stress disorder (PTSD); 
however, no comparative studies have been conducted to 
examine the treatment outcomes in an Asian population. 
The aim of the present trial is to investigate the efficacy 
of CPT (individual format) as a treatment for PTSD in a 
population of Japanese patients.
Methods and analysis A 16-week, single-centre, 
assessor-masked, randomised, parallel-group superiority 
trial has been designed to compare the efficacy of 
CPT in conjunction with treatment as usual (mostly 
pharmacotherapy and clinical monitoring) versus treatment 
as usual alone. The Clinician-Administered PTSD Scale for 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) will be our primary outcome measure 
of the post-traumatic stress symptoms at 17 weeks, 
whereas the PTSD Checklist for DSM-5 and determination 
of the operationally defined responder status will be used 
to assess the secondary outcomes. An estimated sample 
size of 29 participants in each group will be required to 
detect an expected effect size of 1.4 (95% CI 0.85 to 1.95).
Ethics and dissemination The institutional review 
board at the National Center of Neurology and Psychiatry 
in Japan approved this study. The results of this clinical 
trial will be presented at conferences and disseminated 
through publication in a peer-reviewed journal.
Trial registration number UMIN000021670 (registered 
on 1 April 2016).
IntroductIon
Background and rationale
Experiencing a traumatic event can lead to 
a reduced quality of life and may negatively 
affect an individual’s physical and mental 
health. In Japan and many other regions 
around the world, individuals are exposed 
to a vast array of potentially traumatic 
situations, including natural disasters, phys-
ical and sexual assault, intimate partner 
violence, child abuse, among others. For 
example, approximately 33000 Japanese indi-
viduals per year are severely injured or killed 
due to criminal activities, whereas another 
9000 fall victim to rape or sexual assault.1 
Additionally, more than 15000 people died 
because of the Great East Japan Earthquake 
in 2011. Experiencing such events may lead 
to the development of post-traumatic stress 
disorder (PTSD), a debilitating mental 
disorder characterised by intrusion symptoms 
that are associated with the traumatic event, 
as well as avoidance of triggering situations, 
alterations in cognition and mood and hyper-
arousal or reactivity.2 Research has revealed 
that PTSD leads to psychiatric comorbidities, 
an increased risk of suicide and a variety of 
negative health outcomes.3 4 Although the 
prevalence of PTSD in the Japanese popu-
lation is relatively low (an estimated annual 
prevalence of 0.4%5) in comparison with that 
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Protocol
Strengths and limitations of this study
 ► This is the first randomised controlled trial of the 
newest version of individual cognitive processing 
therapy, which does not require the patient to 
provide a written account of the trauma, in a non-
Western context.
 ► This is the largest randomised controlled trial to be 
performed in a Japanese clinical setting for patients 
with post-traumatic stress disorder.
 ► Major limitations include no active treatment control 
group and no restriction of pharmacotherapy 
changes during the intervention period.
.
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of the US population (annual prevalence of 4.7%), care 
and treatment of individuals with PTSD has been far from 
sufficient in Japan.
Systematic reviews, meta-analyses and treatment guide-
lines have consistently reported that trauma-focused 
cognitive behavioural therapies (CBTs) are the treatment 
of choice for individuals with severe PTSD.6–9 Among 
the forms of CBT that have been employed, prolonged 
exposure therapy (PE) and cognitive processing therapy 
(CPT), both of which have been recommended and 
adapted for the treatment of US military veterans, are two 
of the strongest evidence-based treatments for PTSD in 
terms of safety and efficacy.10 Although both treatments 
are classified as CBT, PE focuses on exposure to fearful 
memories associated with the traumatic event, whereas 
CPT focuses on cognitive reappraisal of the meaning of 
the traumatic events and their consequences.
The latest systematic review reported the effect sizes of 
PE and CPT in comparison with wait list or treatment as 
usual (TAU) as having standardised mean differences of 
−1.27 (95% CI −1.54 to −1.00; k=7, n=387) and −1.40 (95% 
CI −1.95 to −0.85; k=4, n=299), respectively.8 9 Research 
has also revealed that CPT and PE are effective in treating 
depression, suicidal ideation and sleep disturbances, in 
addition to reducing the annual costs that are associated 
with providing mental health services.11 Further, CPT 
is highly effective for managing dissociative symptoms, 
improving social adjustment and reducing the chances 
of experiencing intimate partner violence in the future.12
In traditional CPT, now called CPT+A (ie, CPT with 
written accounts),13 the therapist asks the client to write 
and subsequently read aloud a detailed account of the 
traumatic experience. The ultimate goals of CPT+A are 
to break patterns of avoidance and to enable the client to 
modify his or her own cognitive distortions and effectively 
process the associated emotions. The newest version of 
CPT eliminates the use of written accounts, placing more 
emphasis on cognitive processing through patient–thera-
pist interaction and patient engagement in the cognitive 
work.13 The final phase of both treatment programmes 
focuses on five conceptual areas: safety, power/control, 
intimacy, esteem and trust (SPINET). While some 
research has suggested that both CPT+A and CPT are 
effective treatments for the symptoms of PTSD, only four 
randomised controlled trials (RCTs) have demonstrated 
the efficacy of the newer version of CPT in comparison 
with TAU or active psychotherapeutic treatment (one 
using the individual format and three using the group 
format).14–17 Although some studies have examined the 
efficacy of CPT+A or CPT outside of Western cultural 
settings, no comparative clinical trial using the individual 
format of CPT has been conducted in an Asian popula-
tion.15 18 19
Because both patients and therapists are reluctant to 
directly remember or confront the details of a traumatic 
experience using techniques similar to imaginal exposure 
as PTSD treatments, determining the efficacy of cogni-
tive-only CPT is crucial.20 21 A recent study by Larsen et 
al22 revealed that CPT exhibited lower levels of symptom 
exacerbation (14.7%) during treatment than did both 
CPT+A (28.6%) and PE (20.0%). Moreover, the drop-out 
rate was reportedly lower for CPT (22%) than it was for 
CPT+A (34%).16
The present SPINET study aims to investigate the 
safety and efficacy of the latest versions of CPT for the 
treatment of PTSD in a Japanese population in compar-
ison with more commonly used treatment options. There 
are three important aspects to note when discussing the 
design of this RCT. The first is the lack of treatment 
and treatment evidence for PTSD among the Japanese 
population. Only one small Japanese RCT reported the 
efficacy of PE in comparison with that of TAU (n=24, 
standardised mean difference post-treatment=0.95), and 
this prior study excluded patients who had experienced 
domestic violence or childhood trauma.23 Because PE 
is covered by the Japanese Ministry of Health, Labour 
and Welfare, as are more traditional treatments involving 
selective serotonin reuptake inhibitors such as paroxe-
tine and sertraline, CPT may provide an alternative 
treatment option for individuals who have not responded 
to PE or pharmacological interventions. Second, as the 
national CBT training standards in Japan are based on 
Beck’s cognitive theory of depression, clinical imple-
mentation of CPT may be more appropriate because 
CPT itself was developed according to this same theory.24 
Studies involving US military veterans also indicated 
that the degree of CPT implementation is correlated 
with the clinical experience and existing beliefs (eg, 
‘cognitive therapy is clinically effective’) of the therapist 
(r=0.28, p<0.09).25 Hence, CPT administered by trained 
Japanese clinicians is expected to be highly effective for 
improving the clinical outcomes of patients with PTSD. 
Third, it has been suggested that patients with PTSD who 
have had single versus multiple exposures to traumatic 
experiences exhibit different clinical characteristics. For 
example, patients with PTSD who experienced multiple 
traumatic events showed greater functional impairment, 
longer duration and higher comorbidity with mood and 
anxiety disorders.26 Hence, we will employ single versus 
multiple incident trauma as the stratification factor in 
this study.
choice of comparators
The Japanese Society for Traumatic Stress Studies 
published guidelines for the pharmacological treatment 
of patients with PTSD.27 Due to the significant lack of 
clinicians trained in CBT, the recommended first-line 
treatment involves the prescription of either paroxetine 
or sertraline, both of which are classified as selective sero-
tonin reuptake inhibitors. The present study considers 
pharmacotherapy, clinical monitoring, psycho-education 
and supportive counselling, all of which are commonly 
used in the treatment of patients with PTSD in Japanese 
medical settings, as ‘TAU.’
.
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Primary hypothesis and objectives
The primary objective of the present trial is to evaluate the 
hypothesis that the addition of CPT to TAU would result 
in outcomes that are superior to those observed for TAU 
alone with respect to the severity of post-traumatic stress 
symptoms in patients with diagnoses of PTSD, as assessed 
by the Clinician Administered PTSD Scale for the Diag-
nostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5), (CAPS-5). The secondary objective is to 
test the superiority of CPT plus TAU versus TAU alone on 
post-traumatic stress symptoms, as assessed by patients’ 
responses on the PTSD Checklist for DSM-5 (PCL-5) and 
the determination of responder status. The incidence of 
adverse events will also be examined to evaluate the safety 
of CPT for this patient population.
Methods and analysIs
trial design
The SPINET study has been designed as a 16-week, single-
centre, assessor-masked, randomised, parallel-group 
superiority trial that will compare the efficacy of CPT in 
conjunction with TAU versus TAU alone. Minimisation 
will be used to balance the stratification factor of trau-
matic event (single vs multiple/persistent) using a ratio 
of 1:1.
study setting
The SPINET study is being conducted at the National 
Center of Neurology and Psychiatry (NCNP) hospital 
in Japan. The NCNP, located in the suburbs of Tokyo, 
is a national hospital specialising in the research and 
treatment of psychiatric, neurological, muscular and 
developmental disorders. The hospital mainly provides 
secondary or tertiary psychiatric care to socioeconomi-
cally diverse Japanese populations on both an inpatient 
and outpatient basis. Most new patients are referred to 
the NCNP hospital when usual care provided by their 
local institutions has proven ineffective. There is no 
specific department for treating PTSD at this hospital. 
The treatment of PTSD is usually conducted on an 
outpatient basis within the Department of Psychiatry and 
consists of pharmacotherapy, supportive therapy and/or 
active monitoring.
eligibility criteria
Individuals fulfilling the following inclusion criteria will be 
registered to participate in the trial: (1) diagnosis of PTSD 
according to criteria outlined in the DSM-5, as assessed by 
CAPS-5; (2) aged between 18 and 70 years (inclusive) at 
baseline and (3) provision of written informed consent 
prior to participation in the study. Exclusion criteria are 
as follows: (1) severe substance use disorders at baseline, 
as assessed by the Mini-International Neuropsychiatric 
Interview (MINI); (2) current manic episode or psychotic 
disorders at baseline, as assessed by the MINI; (3) serious 
suicidal ideation at baseline, as assessed by the MINI; 
(4) severe or unstable physical disorders or major cogni-
tive deficits at baseline; (5) involvement in manualised 
psychotherapy at baseline and (6) other relevant reasons 
for exclusion, as determined by the investigators (eg, 




The intervention group in the present study will receive 
CPT, a structured psychotherapy for the treatment of 
PTSD, following the comprehensive manual.13 Among 
the various formats of CPT available (eg, group, indi-
vidual, with or without written trauma account), the 
SPINET trial will implement CPT without the use of 
written trauma accounts (ie, the latest version of CPT) 
over an intervention period of 16 weeks. Although CPT 
usually consists of 12 sessions, a maximum of 16 sessions 
will be allowed to approximate the timelines commonly 
used in Japanese medical settings. The number of 
sessions will be determined through discussions among 
the therapist, patient and/or supervisors in consideration 
of the progress of treatment, examining the progress of 
weekly PCL-5 scores. We consider completer status as the 
completion of all 12 sessions of CPT, as outlined in the 
comprehensive manual.13 Treatment will focus on identi-
fying and modifying specific maladaptive cognitive beliefs 
and reactions that have developed owing to experiencing 
the traumatic event. The CPT case formulation will be 
based on the social–cognitive model of PTSD, which 
characterises PTSD as a discontinuation of the natural 
recovery process associated with traumatic events. In the 
CPT framework, such discontinuation, or the process of 
being ‘stuck’, is caused by specific, maladaptive cognitive 
beliefs that inhibit the patient’s ability to process cogni-
tive and emotional information regarding the traumatic 
event and its consequences. For example, one patient 
might have excessive guilt or misattribution regarding the 
traumatic event (eg, “I should have predicted the trau-
matic event and prevented it from occurring”, “The event 
was my fault. I was wrong”). Alternatively, the patient 
might have overgeneralised thoughts (eg, “I have to be 
cautious at all times anywhere I go because the world is 
dangerous”). These maladaptive cognitive beliefs may 
contribute to the maintenance of PTSD symptoms (eg, 
negative mood induced by the excessive guilt or hyper-
arousal induced by the overgeneralisation of danger). In 
CPT, the patient and therapist collaborate to identify and 
challenge such thoughts and beliefs.
In the first session, patients are educated on the 
specifics of this model and asked to write an impact state-
ment, that is, their explanation for why they think the 
event occurred and the event’s consequences, between 
the first and second sessions. The patient and therapist 
use this impact statement to identify the issues unique 
to the patient and to explore the natural emotions asso-
ciated with the traumatic event. Beginning in the third 
session, the patient uses worksheets to learn how to 
monitor his or her own psychological responses and to 
identify the activating events, beliefs and consequences 
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(emotions) associated with such responses (A-B-C work-
sheet).
In subsequent sessions, the patient focuses on acquiring 
the skill of cognitive reappraisal (cognitive restructuring) 
through Socratic questioning by the therapist and prac-
tice using the Challenging Questions Worksheet, Patterns 
of Problematic Thinking Worksheet and Challenging 
Beliefs Worksheet. While the first half of the treatment 
is devoted mainly to challenging the misattributions of 
the causes of traumatic events (ie, self-blame, undoing), 
the last half of CPT is devoted to challenging the beliefs 
associated with the following themes: safety, trust, power/
control, esteem and intimacy.
Psychotherapists involved in the SPINET study must 
be licensed clinical psychologists or physicians who have 
undergone at least 14 hours of CPT training. In addition, 
these therapists must have observed the CPT sessions 
of at least two cases and have experience in conducting 
sessions for at least one case.
Treatment as usual
Following the Japanese treatment guidelines established 
by the Japanese Society for Traumatic Stress Studies,27 we 
expect that the comparison group in the present study 
will receive treatments that are commonly implemented 
in Japanese medical settings, such as pharmacotherapy 
involving paroxetine/sertraline, unstructured supportive 
psychotherapy and/or clinical monitoring. All partici-
pants will be referred by the psychiatrists who are providing 
the TAU. For ethical reasons, treatment by primary care 
physicians will not be restricted, except for systematic 
psychotherapy or electroconvulsive therapy, which will be 
prohibited. The following specifics regarding TAU will 
be documented in each participant’s case report during 
each visit: frequency and duration of treatment, use of 
psychotropic medication, results of the clinical evaluation 
and direction of future treatment.
criteria for discontinuing or modifying allocated 
interventions
The intervention or follow-up observation will be 
discontinued when any of the following occur: (1) the 
participant requests to be removed from the study or 
withdraws consent; (2) inability to contact the participant 
for 1 month; (3) the entire clinical trial has been discon-
tinued and/or (4) any other reasons that the primary 
investigator, therapist or supervisor have deemed worthy 
of discontinuation (eg, hospitalisation or suicide attempt). 
Dates and reasons for discontinuation will be thoroughly 
documented in the case report form. Whenever possible, 
participants will be asked to participate in assessments 
related to the primary and secondary outcomes to deter-
mine the safety and efficacy of the interventions.
strategy and procedures for improving and monitoring 
adherence
All CPT sessions will be audio and/or video recorded. 
Using these recordings, treatment adherence will be 
monitored in weekly group supervision and subsequently 
evaluated using the Cognitive Processing Therapy: Ther-
apist Adherence and Competence Protocol, Individual 
Version—Revised. Supervisors of this study will be MH, 
MI and AyK, each of whom has participated in more than 
48 hours of training. One-fifth of the sessions in each case 
will be subject to evaluations of treatment adherence and 
competence by other therapists in our research team. 
These sessions will be randomly sampled in advance of 
the CPT, and the therapist will not know which sessions 
will be assessed.
strategy for monitoring tau
Participants will be asked to describe the content of TAU 
and occurrence of any adverse events at every visit. When-
ever possible, patient reports of the TAU will be verified 
using electronic medical records.
relevant concomitant care and interventions permitted/
prohibited during the trial
Other forms of systematic psychotherapy or electro-
convulsive therapy will be prohibited during the trial. 
We define ‘systematic psychotherapy’ as any structured 
psychotherapy using published treatment manuals (ie, 
predetermined session numbers and duration, thera-
peutic procedure and content). As changes in the type 
and/or dose of pharmacological agents may be consid-
ered within the scope of TAU, they will be permitted 
during the trial.
outcomes
The CAPS-5 will be used to assess the primary outcome 
measure of PTSD symptoms at 17 weeks, whereas the 
PCL-5 and determination of responder status will be used 
to assess the secondary outcomes at 17 weeks. Because 
there is no current standard operational definition of 
responder status,28 the following criteria will therefore 
be used to determine responder status: (1) clinical global 
impression improvement rating of ≤2, as assessed by 
item 28 of the CAPS-5 and (2) loss of PTSD diagnosis, 
as assessed by the CAPS-5. An additional secondary 
outcome—the safety of the intervention—will also be 
evaluated by examining the incidence of adverse events.
other measures
Additional measures will be included to evaluate outcomes 
related to depression, quality of life, functioning, disso-
ciation and suicidal ideation. Analyses of the treatment 
mechanisms (ie, post-traumatic maladaptive beliefs, trau-
ma-related guilt and emotion regulation) and treatment 
processes (ie, working alliance, homework compliance 
and treatment adherence and competence) will also be 
conducted.
trial timeline
All patients who have primary physicians will be referred 
to this study. Participants who have provided written 
informed consent will be evaluated for trial eligibility. 
Participants confirmed eligible will be registered to 
.
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Figure 1 CONSORT flowchart of the study design. CPT, cognitive processing therapy.
the trial and randomly allocated to either the interven-
tion or control group. The trial timeline is depicted in 
the CONSORT diagram (figure 1) and recommended 
SPIRIT template (table 1).29
sample size
Meta-analyses have revealed that the effect size of Hedges’ 
g is 1.40 (95% CI 0.85 to 1.95, k=4, n=299) for CPT versus 
control groups (eg, TAU, wait list) with respect to post-in-
tervention CAPS scores.6–8 A linear mixed-effects model 
(LMM) will be used to test the primary hypothesis (ie, 
combination of CPT and TAU would be superior to TAU 
only at the 17 week assessment). According to Diggle’s 
formula for estimating the LMM sample size,30 a minimal 
sample size of 3–24 participants in each group is required 
when assuming the following: (two sided) alpha=0.05; 
power=0.9; standardised mean difference=1.40 (95% CI 
0.85 to 1.95); three assessment time-points (pre, middle, 
post); autoregressive covariance structure and within-sub-
jects correlation of 0.2–0.8. Considering a drop-out rate of 
22%,16 a conservative sample size of 29 has been selected.
recruitment
The SPINET trial will be advertised to psychiatrists and 
other physicians in the NCNP hospital and in collabo-
rating clinics in the vicinity. In addition, the trial will be 
advertised at crime victim centres, public health centres 
and departments of health promotion in local govern-
ments. As there is no institute specialised for providing 
psychosocial interventions for patients with PTSD in 
the area, we expect a large number of participant refer-
rals. Because all of the participants must be receiving 
TAU according to our study design, we will not accept 
self-referrals for this study. We estimate two registrations 
per month during the period between April 2016 and 
November 2018.
allocation
Participants will be randomly allocated to either the inter-
vention or the control group in a 1:1 ratio using an online, 
computer-generated sequence. Restricted and adapted 
randomisation (ie, minimisation) will be used to mini-
mise imbalances in the types of traumatic events (single 
.
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Table 1 The schedule of assessments
Time points (weeks) 0 1 2–5 6 7 8 9–10 11 12–16 17 34
Primary and secondary outcomes
  Clinician-Administered PTSD Scale for 
DSM-5 
IE IE IE IE
  Post-traumatic Stress Disorder Checklist 
for DSM-5 
P PtC PtC PtC PtC P/PtC PtC PtC PtC P P
Other outcomes (self-report)
  Patient Health Questionnaire-9 P PtC PtC PtC PtC P/PtC PtC PtC PtC P P
  Suicidal Ideation Attributes Scale P PtC PtC PtC PtC P/PtC PtC PtC PtC P P
  Euro-Qol Five Dimension Five Level P P P P
  Sheehan Disability Scale P P P P
Treatment mechanism
  Posttraumatic Maladaptive Beliefs Scale P P P P
  Trauma-Related Guilt Inventory P P P P
  Emotion Regulation Questionnaire P P P P
Process measures
  Session Rating Scale PtC/T PtC/T PtC/T PtC/T
  Practice Assignment Review T T T T T T T T
  Adverse Event T T T T T/IE T T T IE IE
Additional assessment
  Mini International Neuropsychiatric 
Interview
IE IE IE
CPT, cognitive processing therapy; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; IE, assessment by 
Independent Evaluator; P, patient self-report; PtC, participant during CPT treatment; PTSD, post-traumatic stress disorder; T, therapist self-
report.
event vs multiple/persistent experiences). The clinical 
laboratory technicians of the Clinical Research Unit at 
the NCNP hospital, who will remain independent from 
the research team involved in the SPINET study, will set 
up the online, central randomisation computer software 
for sequence generation with assistance from the trial 
statistician (YK). The principal investigator, therapists 
and members of the research team will not have access to 
the minimisation or probability information. Allocation 
will be implemented by clinical research coordinators or 
primary investigators in front of the eligible participants 
using a laptop computer. Throughout the process, no 
patient or investigator will be able to access information 
that could possibly reveal the allocation.
Masking
Independent evaluators (IEs) will be masked with regard 
to the allocated treatment. Independent evaluators will 
be excluded from all staff meetings, group sessions and 
mailing lists and prohibited from accessing the online 
allocation system. The allocation will not be revealed 
until the final data set has been fixed. The self-reported 
IE Knowledge of Outcome assessment, which has been 
used in a number of clinical trials, will be used to examine 
the success (or failure) of the masking process.31 32 The 
IEs will offer one of three predictions regarding the 
allocation of each participant (intervention, control, 
unknown). On completion of the trial, a table containing 
these predictions alongside the actual allocation data will 
be used to calculate the masking index.33 No emergent 
circumstances will be assumed to unblind the allocation 
to the IEs because the treatment is known to the patients, 
therapists and primary doctors.
data collection
Assessment of outcomes will follow the schedule presented 
in table 1. The details for each assessment are included as 
online supplementary material, and thus, the assessments 
are only briefly outlined below. For the primary and 
secondary outcomes related to PTSD symptoms and diag-
nosis, the monthly version of the CAPS-5 and PCL-5 will 
be used to assess the severity of PTSD symptoms and to 
diagnose cases.34 35 Traumatic events will be assessed using 
the Life Events Checklist-5 before the administration of 
CAPS-5.36 For the other aspects of clinical outcomes, 
the Patient Health Questionnaire-9 (PHQ-9), Suicidal 
Ideation Attributes Scale (SIDAS), Euro-Qol Five Dimen-
sion Five Level (EQ-5D-5L) and Sheehan Disability Scale 
(SDS) will be used to assess depression, suicidality, quality 
of life and functional impairment, respectively.37–40 To 
assess the treatment mechanisms focusing on the content 
and process of cognitive processing, the Posttraumatic 
Maladaptive Beliefs Scale, Trauma-Related Guilt Inven-
tory, and Emotion Regulation Questionnaire will be 
.
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used.41–43 For the process measures of the intervention, 
we will assess therapeutic alliance, homework adherence 
and safety by using the Session Rating Scale,44Practice 
Assignment Review45 and the question set of adverse 
events, respectively. To assess adverse events, therapists 
or IEs will question patients regarding the occurrence or 
worsening of any symptoms during each visit. The severity 
of adverse events will be assessed using criteria from the 
Japanese version of the Common Terminology Criteria 
for Adverse Events (V.4.0).46 The MINI 7.0.0., which 
is a widely used, short, structured diagnostic interview 
developed to evaluate psychiatric disorders according 
to DSM-5 and ICD-10 criteria,47 will be used to ascertain 
the exclusion criteria and other psychiatric disorders. All 
assessment sessions will be audio-recorded, and different 
IEs will evaluate one-fifth of the randomly sampled 
audio-recorded sessions to determine the inter-rater reli-
ability of the CAPS-5.
Plan to promote participant retention and complete follow-
up
To promote transparency, the allocation process will be 
conducted by the trial coordinator in front of the partic-
ipant and their designated CPT therapist using a laptop 
computer. Participants disappointed by their allocation 
to the control group will receive, if necessary, minimal 
emotional support and assistance in engaging in their 
TAU from the CPT therapist who will also emphasise that 
the participant can start CPT 18 weeks later. The partic-
ipant can then schedule their CPT appointments, which 
will start at week 18. The allocation session will take about 
50 min. After each assessment point, the results will be 
summarised and sent to participants along with motiva-
tional messages designed to promote adherence to the 
trial. Participants who drop out or meet any criteria for 
discontinuation will still be asked to participate in the 
week 17 assessment. This request will be emphasised to 
the participant at the time of informed consent. No mone-
tary or physical incentives will be provided to patients at 
any point during the assessment or intervention.
data management
All assessment and case report data will be entered into 
a Microsoft Access (Microsoft) database. To prevent 
keystroke errors, the database will be configured such that 
only those numbers within the range of possible scores 
will be accepted (eg, only entries of 1–5 will be allowed 
when the range of possible scores for the item is 1–5). 
New data will be immediately saved to the hard drive and 
encrypted by the trial staff. Data entry will be conducted 
using a standalone computer without any connection to 
the Internet. Entered data will be confirmed by a second 
person. Only individuals who have received permission 
from the primary investigator will be allowed access to the 
database. Original paper records for each participant will 
be stored according to binder type (ie, paper materials 
related to the assessments will be stored in an assess-
ment binder and intervention materials will be stored in 
a separate intervention binder). The paper binders will 
be stored in numerical order in a locked cabinet at the 
National Center for Cognitive-Behavior Therapy and 
Research within the NCNP. The paper files will be stored 
for a period of 5 years after trial completion.
statistical methods
The statistician for this trial (YT) will analyse the data. 
Primary outcomes will be analysed using an LMM and 
autoregressive repeated covariance type. Patient scores 
on the CAPS-5 will be considered dependent variables. 
Group allocation (intervention=0, control=1), assessment 
time point (baseline=0, week 8=1, week 17=2), and the 
interaction between group allocation and assessment 
time point will be regarded as fixed-effect factors, whereas 
participant will be regarded a random-effect factor. Statis-
tical significance will be set at p<0.05 for two-tailed t-tests. 
Analyses of secondary outcomes (eg, PCL-5) and other 
exploratory outcomes (PHQ-9, EQ-5D-5L, SIDAS, SDS) 
will be conducted in the same fashion. The proportion 
of individuals considered responsive to treatment will be 
examined using a risk ratio with a 95% CI. Safety will be 
evaluated using a cross-table for the occurrence of adverse 
events. Subgroup analyses have not been planned at this 
time. Up-to-date versions of R will be used to analyse the 
data. Following the intent-to-treat principle, data from all 
allocated participants will be used to examine the safety 
and efficacy of the interventions. However, secondary 
analysis of all data not meeting the discontinuation 
criteria will be conducted using a per-protocol approach. 
Although we consider that the LMM is capable of 
resolving the problem of missing values, a multiple impu-
tation method analysis will be conducted as a sensitivity 
analysis. Missing values related to secondary or explor-
atory outcomes will be handled similarly.
data monitoring
The primary investigators of the SPINET study, in collabo-
ration with the study coordinators and data manager, will 
conduct on-site and central monitoring and will report 
the results to the Data and Safety Monitoring Board 
(DSMB). The DSMB consists of two psychiatrists who will 
remain independent of all activities associated with this 
clinical trial. On-site monitoring (ie, checking the congru-
ence of the entered data with respect to the original case 
report forms/assessments) will be conducted by the data 
manager following a checklist developed in advance of 
the study. The first three registered cases along with three 
randomly presampled cases selected from among cases 4 
to 29 will undergo on-site monitoring. Cases to undergo 
on-site monitoring will not be disclosed to personnel who 
complete the data entry and/or fill in the case report 
forms. If significant errors/issues are discovered during 
on-site monitoring, additional on-site monitoring will be 
conducted. All registered cases will undergo central moni-
toring by the trial statistician every 6 months (at the end 
of March and October). The primary investigators and 
members of the DSMB have the right to designate DSMB 
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meeting locations. Members of the DSMB can request 
that the data manager share specific study information.
Plans for an interim analysis have not been formulated 
at this time. The SPINET trial will be stopped when the 
institutional review board (IRB) and/or DSMB recom-
mends doing so. The primary investigators and members 
of the DSMB will evaluate the continuation of the trial if 
any of the following occur: (1) the primary investigator 
obtains important information regarding the quality, 
safety and efficacy of the intervention or (2) the IRB 
requests a change to the study protocol that is difficult to 
implement.
assessment of harm and invasiveness
Invasiveness is defined as the occurrence of physical or 
mental harm or the experience of significant burden by 
participants due to any purposeful research act, including 
questioning regarding psychological trauma.48 49 Such 
questions will be included in the assessments (ie, CAPS-5, 
PCL-5) and interventions used in the SPINET study. 
Because these questions are routinely implemented in 
standard clinical practice for the treatment of PTSD and 
are not considered to result in permanent alterations to 
a patient’s psychological state, we believe that the treat-
ments used in the present study are minimally invasive. 
Information regarding the occurrence of adverse events 
will be solicited from patients according to a previously 
described protocol, with particular focus on suicidal 
ideation, as assessed using the SIDAS. Should an adverse 
event occur, the investigator (ie, or therapist) will assess 
and document the content, duration, severity, outcome 
and relatedness of the event to trial participation. Severe 
adverse events will be defined according to established 
ethical guidelines in Japan, as follows: death, threat to 
life requiring inpatient treatment, permanent or signifi-
cant disorder/dysfunction or development of congenital 
anomaly. Details regarding severe adverse events will be 
immediately reported to the IRB of the NCNP. Other 
information related to adverse events will be reported to 
the DSMB every 6 months and to the IRB once per year.
auditing
Auditing of data has not been planned at this time.
ethIcs and dIsseMInatIon
ethical approval, protocol amendments, consent
The SPINET study has been approved by the IRB of the 
NCNP (approval number: A2015-111; 16 March 2016). 
Approval from the NCNP will be required to change the 
protocol, forms and documents used to obtain informed 
consent. Details of the SPINET study will be explained 
to patients prior to their participation in the study by the 
primary investigator or research coordinator using an 
informational leaflet. Written informed consent will be 
obtained from patients who agree to participate in the 
study. Informed written assent and consent will be obtained 
from both patients and their guardians/family members in 
cases where participants are under the age of 20.
confidentiality
All data obtained will be securely stored at the NCNP. 
The collected paper documents will be filed separately 
according to participant. These files will be stored in a 
locked cabinet located in a doubly locked room. All iden-
tifying information associated with specific participants 
will be excluded from paper files. All identifying informa-
tion will be recorded with a participant number to secure 
patient privacy, and no personal identity-related informa-
tion will be entered into the electronic database. The key 
connecting the participant numbers and names (as well 
as contact and tracking information) will be kept sepa-
rate from the data files. The electronic database and all 
other electronic data (ie, audio or video recordings) will 
be saved to an encrypted hard drive with a password lock. 
The hard drive will be stored in the locked cabinet along 
with the paper files. Data entry and statistical analyses 
will be conducted using a standalone computer without 
any connection to the internet or hospital intranet. All 
other papers with identifying information (ie, signed 
informed consent forms) will be stored in a separate 
locked cabinet.
access to data
Prior to publication of the primary outcome paper, only 
the data manager will have access to the full data set. 
The data manager will verify any problems (eg, missing 
data, illogical data) in the data and finalise the data set 
for statistical analysis. Following publication, only the 
primary investigators and those individuals who receive 
approval from the primary investigators will have access 
to the cleaned data set.
ancillary and post-trial care
During and following participation in the SPINET study, 
participants will be allowed to contact the trial coordi-
nators. If any adverse events requiring additional care 
occur, the principal investigator will arrange appro-
priate medical or psychological care. Patients will not be 
compensated for medical costs related to harm caused by 
adverse events. If harm occurs, we will provide necessary 
treatment by using the participant’s health insurance, 
because the occurrence of harm beyond that typically 
associated with the care provided in the trial is not 
expected.
dissemination policy
Regardless of the results, the primary outcome will be 
published in a peer-reviewed journal. In addition, a 
summary of the results will be provided on our website to 
alert the participating physicians, medical staff and partic-
ipants of the findings and scientific significance of the 
study. Exploratory analyses of the data will be conducted 
to examine the treatment parameters (ie, relationships 
between the intervention outcome and trauma-related 
cognition, treatment and demographic variables) and 
identify the sequence of symptom recovery.
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dIscussIon
There is a substantial need for care among individuals 
with PTSD and related difficulties in Japan. This clin-
ical trial is expected to provide evidence of the efficacy 
and safety regarding one of the most disseminated PTSD 
treatments, CPT, among Japanese patients with PTSD. 
Although we designed this trial to achieve higher scien-
tific validity, we had to abandon the application of more 
rigorous conditions for conducting the trials owing to 
feasibility issues in managing the trial in the Japanese 
medical setting. Three major limitations of the study exist 
regarding the control conditions and participant charac-
teristics. The first limitation is that we could not employ 
active control conditions, such as PE or present-centred 
therapy. Hence, we will not be able to conclude the supe-
riority of CPT to the common therapeutic factors or 
other established treatments (ie, PE), although that is not 
our primary focus. Second, we will not be able to limit 
changes to pharmacotherapy during the course of this 
study because participant recruitment would be hindered 
by doing so in Japan. Third, the participants cannot self-
refer to the study, which limits the generalisability of the 
results. Despite these limitations, this study is expected to 
provide useful information regarding the applicability of 
CPT in the Japanese settings and population.
current study status
The SPINET study began recruiting participants on 1 
April 2016. Three participants have been enrolled at the 
time of submission of this protocol.
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